Immunoprecise Antibodies Ltd
XTSX:IPA
Immunoprecise Antibodies Ltd
XTSX:IPA
Price:
6.5 CAD
0.78%
Market Closed
Updated:
May 10, 2024
Immunoprecise Antibodies Ltd
Gross Profit
|
Immunoprecise Antibodies Ltd
Gross Profit Peer Comparison
Comparables:
ABCL
ARCH
RP
IOT
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Immunoprecise Antibodies Ltd
XTSX:IPA
|
Gross Profit
CA$11.5m
|
CAGR 3-Years
68%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Arch Biopartners Inc
XTSX:ARCH
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innovotech Inc
XTSX:IOT
|
Gross Profit
CA$811.6k
|
CAGR 3-Years
-2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
5%
|
See Also
What is Immunoprecise Antibodies Ltd's Gross Profit?
Gross Profit
11.5m
CAD
11.5m
CAD
Based on the financial report for Apr 30, 2021, Immunoprecise Antibodies Ltd's Gross Profit amounts to 11.5m CAD.
What is Immunoprecise Antibodies Ltd's Gross Profit growth rate?
Gross Profit CAGR 3Y
68%
68%
Over the last year, the Gross Profit growth was 44%. The average annual Gross Profit growth rates for Immunoprecise Antibodies Ltd have been 68% over the past three years .
You don't have any saved screeners yet
